VALN Earnings

VALN reported its earnings on 2026-05-13, showcasing a revenue of 36.16M against an estimate of 46.27M, resulting in a -21.84% surprise. The EPS was -0.42, surpassing the expected -0.21 by -100%. The stock experienced a -2.17% price change on the earnings day and a -4.83% change over the next five days, reflecting market reactions to the results.

Following VALN's earnings announcement on 2026-05-13, the stock price moved by -2.17% on the day of the release. Over the subsequent five days, it saw a -4.83% change. Historically, VALN's stock price tends to shift by an average of -5.14% in the 10 days leading up to earnings and -0.21% in the 10 days following, providing insight into potential market.

For , analysts estimate VALN's annual revenue to reach undefined, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between VALN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, VALN's stock price typically moves by -5.14% in the 10 days before its earnings and -0.21% in the 10 days after. For the upcoming earnings, analysts expect an EPS of undefined and revenue of undefined.

The earnings call reveals several concerning factors: declining gross margins, increased losses, and higher financial expenses. The Q&A section highlights uncertainties regarding the Lyme disease vaccine's clinical evidence and FDA interactions. Additionally, the decline in IXIARO growth and potential revenue risks due to geopolitical factors contribute to a negative outlook. While there are efforts to address concerns and expand the R&D pipeline, the lack of clear guidance and immediate positive catalysts suggest a negative stock price movement in the short term.